Search Within

Veronica Miriam Rotemberg

  1. "Surgery"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (4)
  3. Research Letter (3)
Groups
  1. Department of Medicine (13)
  2. Dermatology (13)
  3. Dermatology Service (13)
  4. Division of Subspecialty Medicine (13)
  5. Melanoma Disease Management Team (13)
  6. Surgery (13)

More Groups

People
  1. Eli Diamond (11)
  2. Mario Lacouture (11)
  3. Benjamin Durham (9)
  4. Jasmine Francis (9)
  5. Kseniya Petrova-Drus (9)
  6. Mariko Yabe (9)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (6)
  4. 2022 (2)
  5. 2021 (1)
  6. 2020 (1)

More Years

Publications
  1. Blood (3)
  2. Pediatric Blood and Cancer (3)
  3. British Journal of Haematology (2)
  4. British Journal of Dermatology (1)
  5. Journal of Clinical Oncology (1)
  6. Leukemia (1)

More Publications

Publishers
  1. American Society of Hematology (3)
  2. Nature Publishing Group (3)
  3. Wiley Periodicals, Inc (3)
  4. John Wiley & Sons (2)
  5. American Society of Clinical Oncology (1)
  6. Blackwell Publishing (1)

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease
    Research Letter

    Goyal, G.; Reiner, A. S.; Bossert, D.; Sigler, A. M.; Lacouture, M. E.; Rotemberg, V.; Francis, J. H.; Go, R. S.; Rampal, R. K.; Diamond, E. L.
    Blood (2025)

    Fulltext@MSK | Save
  • Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
    Journal Article

    Friedman, J. S.; Durham, B. H.; Reiner, A. S.; Yabe, M.; Petrova-Drus, K.; Dogan, A.; Pulitzer, M.; Busam, K. J.; Francis, J. H.; Rampal, R. K.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Outcomes with MEK inhibitor therapy among adults with Langerhans cell histiocytosis (LCH): A multi-institutional study from the Adult LCH Working Group for the Histiocyte Society
    Meeting Abstract

    Goyal, G.; Acosta Medina, A. A.; Cao, X.; Bossert, D.; Matthew, P. C.; Makras, P.; Abdel-Wahab, O.; Abeykoon, J. P.; Amerikanou, R.; Bach, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long-term outcomes with single-agent BRAF-inhibitor therapy in Erdheim-Chester disease
    Meeting Abstract

    Goyal, G.; Reiner, A.; Bossert, D.; Sigler, A.; Buthorn, J.; Lacouture, M.; Rotemberg, V.; Francis, J. H.; Go, R. S.; Rampal, R. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
    Journal Article

    Reiner, A. S.; Durham, B. H.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V.; Abdel-Wahab, O.; Panageas, K. S.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition
    Research Letter

    Diamond, E. L.; Francis, J. H.; Lacouture, M. E.; Rotemberg, V.; Yabe, M.; Petrova-Drus, K.; Ulaner, G. A.; Reddy, R.; Abdel-Wahab, O.; Durham, B. H.
    Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Rosenblum, M.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V. M.; Hatzoglou, V.; Young, R.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • A multinational series of 26 patients with mixed histiocytic neoplasms highlighting a diverse mutational landscape and superior efficacy of targeted therapies
    Meeting Abstract

    Diamond, E. L.; Durham, B. H.; Reiner, A. S.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Ulaner, G. A.; Reddy, R.; Lacouture, M. E.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Yabe, M.; Petrova-Drus, K.; Rosenblum, M.; Rotemberg, V.; Lacouture, M. E.; Rampal, R.; Francis, J.; Knoerzer, D.; Kreider, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Risk of nonacral cutaneous melanoma after the diagnosis of acral melanoma
    Research Letter

    Kurtansky, N. R.; Manci, R. N.; Bello, D. M.; Adamson, A. S.; Shoushtari, A. N.; Wehner, M. R.; Ariyan, C. E.; Marghoob, A. A.; Marchetti, M. A.; Rotemberg, V.
    British Journal of Dermatology (2022)

    Fulltext@MSK | Save